89bio, Inc. ETNB
At closeOct 30, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +89.77%
- 1 year
- +85.73%
- Market cap
- 2.20B
- Shares out
- 148.49M
- YTD return
- +89.77%
- 1-year return
- +85.73%
- Volume
- 38.51M
- Open
- 14.84
- Previous close
- 14.84
- Day's range
- 14.84 – 14.84
- Analysts
- Buy
- Price target
- 30.38 (+104.7%)
Key statistics
- Enterprise value
- 1.68B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -257.73M
- Total cash
- 561.16M
- Total debt
- 37.62M
- Return on equity
- -86.86%
- Short % of float
- 6.30%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
- Target (low)
- 14.50
- Target (mean)
- 30.38
- Target (high)
- 55.00
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -0.50 | -1.39 | -0.89 | -178.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.49 | -0.71 | -0.22 | -44.90% |
| May 1, 2025 | Mar 31, 2025 | -0.50 | -0.49 | +0.01 | +2.00% |
| Feb 27, 2025 | Dec 31, 2024 | -0.60 | -1.02 | -0.42 | -70.00% |
| Nov 7, 2024 | Sep 30, 2024 | -0.64 | -1.39 | -0.75 | -117.19% |
| Aug 5, 2024 | Jun 30, 2024 | -0.57 | -0.48 | +0.09 | +15.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 19, 2025 | Raymond James | down | Outperform | Market Perform |
| Sep 19, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 19, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 25, 2025 | B of A Securities | main | Buy | Buy |
| Aug 8, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Mar 14, 2025 | Goldman Sachs | init | — | Neutral |
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 89bio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ETNB — it syncs with the Stock Master app.